Efficacy of Thymosin alpha1 for Severe Sepsis

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy of thymosin alpha 1 for treating severe sepsis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Thymalfasin

Criteria

Inclusion Criteria:

• Severe sepsis according to ACCP/CCM criteria

• Patient or legally authorized representative able to provide informed consent

Exclusion Criteria:

• Subject is less than 18 years or more than 85 years of age

• If female, the subject is pregnant or nursing

• Subject is receiving immunosuppressive therapy such as cyclosporine, azothioprine,or cancer-related chemotherapy

• Patient not expected to survive 28 days because of uncorrectable medical condition, such as poorly controlled neoplasm or other end-stage disease

• History of bone marrow, lung, liver, pancreas, or small-bowel transplantation

• Acute pancreatitis with no established source of infection